Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Disease burden disease burden in 2000 could be attributed to the effects of (short-term) exposure to air pollution, noise, radon, natural UV radiation, and dampness in houses. The percentage can increase to up to 13% due to uncertainty, assuming no threshold. Among the investigated factors, long-term PM10 exposure have the greatest impact on public health. As levels of PM10 decrease, related disease burden is also expected to decrease. Noise exposure and its associated disease burden is likely to increase to a level where the disease burden is similar to that of traffic accidents. The rough estimates do not provide a complete picture